Prime.io Ltd helps antibody and drug target validation teams to generate high-quality knock-in and knock-out cell models—fast. Powered by our proprietary AI designed CRISPR platform (commercial licence available), we deliver:

• 3x higher knock-in efficiency than conventional spCas9 in pool and single cancer/iPSC cell derived clone 


• Up to 97% knock-out efficiency in single cancer/iPSC cell derived clone


• Reduced off-target activity and immunogenicity


• NGS-validated single-cell clones


• Single cell derived edited clone delivery in just 8–12 weeks (if cell doubling rate is around 24 hrs)

From design to validated clone delivery, we provide a seamless, end-to-end service. No licensing restrictions. Full IP ownership. Scientific support included.

Prime.io CEO Rex is looking forward to connect with you at Bio-Europe Spring Lisbon.